Journal of Hepatology
Volume 58, Issue 4 , Pages 792-800, April 2013
David Burger, David Back, Peter Buggisch, Maria Buti, Antonio Craxí, Graham Foster, Hartwig Klinker, Dominique Larrey, Igor Nikitin, Stanislas Pol, Massimo Puoti, Manuel Romero-Gómez, Heiner Wedemeyer, Stefan Zeuzem
Received 17 August 2012; received in revised form 22 October 2012; accepted 25 October 2012. published online 06 November 2012
Summary
Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug–drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug–drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted drug–drug interaction studies and a list of contraindicated medications is not enough for the clinical management of these drug–drug interactions. Knowledge of pharmacokinetic profiles and concentration–effect relationships is key for the interpretation of these data, and insight into how to manage these interactions (e.g., dose adjustments, safe alternatives and therapeutic drug monitoring) is of equal importance. This review provides a practical overview of the safe and effective management of these clinical challenges.
Abbreviations: HCV, hepatitis C virus, DAAs, direct-acting antivirals, HIV, human immunodeficiency virus, SPCs, summary of product characteristics, Peg, polyethylene glycol, BID, twice daily, AKR, aldo-ketoreductases, P-gp, P-glycoprotein, AUC, area under the plasma concentration vs. time curve, FDA, Food and Drug Administration, EMA, European Medicines Agency, TDM, therapeutic drug monitoring, CYP, cytochrome P450, ECG, electrocardiogram, UGT, UDP-glucuronosyltransferase, ACE, angiotensin converting enzyme, AT1, angiotensin II receptor, PDE5, phosphodiesterase type 5, BOC, boceprevir, TVR, telaprevir, RBV, ribavirin, IFN, interferon
Keywords: Drug interactions, Hepatitis C virus infection, Boceprevir, Telaprevir, Pharmacokinetics
Introduction
With the introduction of the direct-acting antivirals (DAAs) telaprevir and boceprevir in Europe, US and other countries in 2011–2012, the management of drug–drug interactions in the treatment of patients with hepatitis C virus (HCV) has gained wide interest. Drug–drug interactions were not entirely new to the field, as certain combinations of ribavirin and human immunodeficiency virus (HIV) nucleoside analogues had been shown to be problematic before [1], and transplant hepatologists have long learned to consider drug–drug interactions with ciclosporin and tacrolimus. The current attention on drug–drug interactions and their clinical management, however, is unprecedented in hepatology and many other disease areas, and can only be compared to the introduction of HIV-protease inhibitors in the mid-90s.
Each health professional involved with HCV treatment (hepatologist, infectious disease specialist, nurse specialist, clinical pharmacist, etc.) will need a sound and complete understanding of the potential of a drug–drug interaction in every patient treated for HCV infection. This is a rapidly evolving field and many questions on specific drug combinations remain unanswered. Most of the drug–drug interaction studies are initially presented at conferences and many do not appear in peer-reviewed literature. Besides knowledge on potential mechanisms that form the basis of the development of drug–drug interactions, one should also have an overview of the most frequently occurring or most serious potential drug combinations. Finally, awareness of how to find reliable and up-to-date information is essential.
One of the reliable and up-to-date sources is a website from the University of Liverpool: www.hep-druginteractions.org. However, since only a small number of interactions have been studied, one of the challenges is to provide expert opinion on potential interactions based on metabolic data and an understanding of the mechanisms. Currently, the website does not always provide information on effective alternatives when faced with a problematic interaction, and this would be a useful addition.
In this paper, we will review drug interactions with HCV agents and a number of therapeutic groups. As (potential) drug interactions between HIV and HCV drugs are extensive [2], it was decided that this deserves a separate review and, therefore, this will not be included here. Also, alternative and complementary medicines (e.g., herbals) may cause drug interactions but have not yet been studied and are consequently not the scope of this paper. Before discussion of potential drug interactions with anti-HCV agents, the pharmacokinetic properties of the drugs and current knowledge of their concentration–effect relationships will be discussed. This basic knowledge is required for an adequate interpretation of drug interaction data. It is important to remember that drug–drug interactions can be bidirectional, i.e., both drugs are affected.
Data on drug interactions were extracted from published literature, Summaries of Product Characteristics (SPCs) [3], [4], abstract books from medical conferences, and clinical experience. If possible, a safe alternative is given to manage a specific drug interaction although it should be noted that clinical experience is limited. Data have been updated until July 1, 2012 and this overview is restricted to licensed anti-HCV agents.
Pharmacokinetics of anti-HCV agents
This paragraph focuses on the currently available anti-HCV agents ribavirin, polyethylene glycol (Peg)-interferon alfa, telaprevir and boceprevir. Ribavirin is a nucleoside analogue and as such a prodrug requiring intracellular activation to a triphosphate. Ribavirin-triphosphate accumulates in red blood cells because these cells lack the enzyme to degrade the triphosphate. Ribavirin has a bioavailability of approximately 64%, which is largely dependent on simultaneous intake of food. Absorption is dose-limited, so it is recommended to take ribavirin twice-daily (BID), although based on its long elimination half-life (approximately 300
Interferon alfa is a recombinant representative of a natural protein that can only be administered parenterally; its pharmacokinetic profile is improved by encapsulation of the molecule in a peg “coat”. As a result, dosing frequency could be reduced to once-weekly subcutaneous administration. There are 2 forms marketed: 2a and 2b, which have limited pharmacokinetic differences, and in this paper interferon alfa is meant to represent both 2a and 2b products. Peg-interferon alfa is not a substrate of hepatic metabolism and does not show a direct inducing or inhibitory effect on hepatic metabolism of other agents.
Boceprevir and telaprevir are both orally available HCV protease inhibitors with food-dependent absorption and relatively short elimination half-lives, necessitating three times daily administration (BID administration of telaprevir is currently in phase III clinical trial). Both agents are substrates of CYP3A, although for boceprevir this is not the primary route of metabolism; boceprevir is primarily metabolised by aldo–ketoreductases (AKR) and only a minor proportion is subject to CYP3A-mediated metabolism [5]. Both boceprevir and telaprevir are substrates of the membrane transporter P-glycoprotein (P-gp), which is present at many sites, including the gastro-intestinal tract, blood–brain barrier, placenta; P-gp is a so-called efflux pump and prevents uptake of substrates, and as such can be seen as a protection of the body against noxious substances. Telaprevir and boceprevir are both strong inhibitors of CYP3A, with telaprevir being associated with a stronger inhibitory effect than boceprevir (see data on immunosuppressants and midazolam below). Both agents also appear to be inhibitors of P-gp (again, with boceprevir being a weaker inhibitor than telaprevir, based on digoxin data), but it should be noted that this is more difficult to assess as a large overlap between CYP3A and P-gp substrates exists. Both agents are so-called mechanism-based inhibitors of CYP3A, which means that CYP3A is inactivated. As a consequence, reduced CYP3A activity is maintained even when telaprevir or boceprevir use is discontinued, until new CYP3A enzymes are generated (approximately 1
Based on the above, much attention will be directed to interactions between boceprevir/telaprevir on one hand and CYP3A/P-gp substrates/inhibitors/inducers on the other hand.
Concentration, effect relationships
It is difficult to interpret results from drug–drug interaction studies without a detailed insight into concentration–response relationships. If there is no change in plasma concentrations when drug A is added to drug B, one can easily conclude that both agents can be safely combined from a pharmacokinetic perspective. But what changes in drug concentrations is generally accepted to be related to reduced efficacy: −30%,−50% or −70%? At which elevated drug concentration is the risk for toxicity significantly increased? Which pharmacokinetic parameter is most closely associated with therapeutic response and thus should be used for interpretation: the average exposure to the drug during one dose interval (area-under-the-concentration vs. time curve, AUC), or for instance the trough concentration (Cmin)? A sensible statement can only be made if a concentration–effect relationship is known, there is some idea of a target concentration, how far away the “average” patient is from this putative threshold and how large the interpatient variability is in pharmacokinetics. It is not surprising that in clinical practice such a well-balanced and thorough evaluation of drug interaction data is hardly possible, and inevitably we have to look at drug interaction data outcomes in a more general way. Regulatory bodies such as the Food and Drug Administration (FDA) or European Medicines Agency (EMA) could decide that any reduction in exposure of more than a certain percentage (i.e., 30%, 40%, 50%) could be defined as clinically relevant, and hence any combination of drugs that leads to this kind of plasma drug concentration change should lead to either a dose adjustment or a contraindication. Such a general condition can then be applied to agents with comparable mechanisms of action and pharmacokinetic properties. This is, however, difficult to justify given differences in concentration, effect relationships and is currently not an FDA or EMA viewpoint.
Another important consideration is that in pharmacokinetic studies, plasma (or serum) pharmacokinetic parameters are assessed, while it is known that anti-HCV agents are primarily active inside the hepatocyte and not in plasma. Hepatocytes, however, do not represent an easily accessible biological matrix. Animal data may not always reflect the human situation, as there are differences in expression of uptake transporters between species [6]. As a result, we tend to assume that globally, there is a correlation between concentrations at the site of activity and in plasma, and hence changes in plasma concentrations will result in more or less similar changes inside the hepatocyte. For all DAAs, correlations have been found between plasma concentrations and HCV RNA decline after the start of treatment [7], [8]. Thus, the assumption that plasma concentrations are a surrogate for levels inside the hepatocyte appears valid so far. However, in individual patients, there could be a “mismatch” between plasma and hepatocyte concentrations, for instance caused by genetic polymorphisms in uptake or efflux transporters present on the cell membrane of a hepatocyte. Another example of a mismatch could be for nucleoside analogues that are activated intracellularly to triphosphates: plasma concentrations of the parent compound may not always be related to intracellular concentrations of the triphosphate.
A further important aspect is the possibility to use therapeutic drug monitoring (TDM) to assess the presence of a clinically relevant drug interaction. TDM can play a major role in the management of a drug–drug interaction and to evaluate the effectiveness of an intervention such as a dose adjustment. For anti-HCV agents, this is currently only possible for ribavirin in a number of specialized laboratories. Literature suggests that steady-state plasma concentrations of ribavirin at week 8 or later should be 2.0
Immunosuppressive agents (including steroids)
Without doubt one of the most important drug interactions with the currently available anti-HCV agents are those with immunosuppressants, such as tacrolimus and ciclosporin [10]. These immunosuppressants are substrates of both CYP3A and P-gp and, with the above-described inhibitory effects of boceprevir and telaprevir on CYP3A and P-gp, it was expected that the plasma concentrations of the immunosuppressants would be largely increased. In particular, the interaction between tacrolimus and telaprevir has a magnitude that is unprecedented in clinical pharmacology: the AUC of tacrolimus is increased by 70.3-fold and this combination would be lethal if doses are not adjusted [11]. Ciclosporin levels are increased “only” 4.1-fold when combined with telaprevir. Also for boceprevir, the interaction with tacrolimus is stronger than for ciclosporin, but differences are less pronounced than for telaprevir: tacrolimus levels increase 17-fold and ciclosporin levels 2.6-fold when combined with boceprevir [12]. Less attention has been paid to the effects of the immunosuppressants on the levels of the HCV protease inhibitors, but no influence is expected.
The above-mentioned data have been collected in healthy volunteers; preliminary data presented at EASL 2012 suggest that with TDM of immunosuppressants directly from the start of combined treatment these combinations are indeed manageable with adjusted doses that appear to be around 50% of the observed differences in healthy volunteers [13]. Overall, the ciclosporin dose needed to be adjusted by an average factor of 1.3 while the interaction study in healthy volunteers showed a 2.6-fold increase. However, in this study, patients were admitted to hospital for correction of drug dosing and intensively monitored. Phase II studies are ongoing that might allow less intensive monitoring and more flexible dosing of the immunosuppressants, for instance a very low dose of tacrolimus taken once-a-week when combined with telaprevir. At the current time, there is some uncertainty whether the safety and efficacy of tacrolimus once weekly (with telaprevir) can be extrapolated from daily use of tacrolimus (without telaprevir), even when similar target trough levels of tacrolimus are achieved. The combination of ciclosporin and boceprevir causes the smallest interaction and could be considered a preferred option. There are no data on the use of other immunosuppressants such as sirolimus and everolimus, but it is expected that the effects are similar to those with tacrolimus.
Systemically applied corticosteroids such as prednisone and methylprednisolone are CYP3A substrates and higher steroid levels may occur when combined with telaprevir and boceprevir, and this is not recommended. This also holds true for corticosteroids that are locally applied by inhalation or intranasally such as budesonide and fluticasone: Cushing syndrome may occur with DAAs. Regarding the systemic glucocorticoid dexamethasone, this agent can act as an enzyme inducer and may be associated with low DAA levels. There are data available suggesting that beclomethasone can be used safely in patients on strong CYP3A inhibitors [14] and consequently this could be the corticosteroid of choice for patients on HCV protease inhibitors. Dermatically applied steroids are not expected to cause significant systemic absorption; this could be different for anorectal administration to treat anorectal discomfort.
Antimicrobial agents (non-HIV)
Ketoconazole is a prototype CYP3A inhibitor often used during clinical development of putative CYP3A substrates such as telaprevir and boceprevir to investigate interactions. It has been shown that telaprevir levels were increased by 62% and also ketoconazole levels were elevated by 46–125%, demonstrating telaprevir’s CYP3A/P-gp inhibitory potential [15]. It is recommended that telaprevir can de dosed normally, but that the ketoconazole dose should not exceed 200
Besides ketoconazole, the macrolide clarithromycin is a well-known CYP3A inhibitor. Plasma concentrations of boceprevir were only marginally increased (+21%) during co-administration and, therefore, these agents can be safely combined without dose adjustments [16]. Telaprevir has not been tested with clarithromycin, but a similar recommendation can be given. The potential increase in clarithromycin levels, however, warrants electrocardiogram (ECG) monitoring in patients also on telaprevir, as QT prolongation may occur. Where possible, azithromycin is an alternative to clarithromycin, as the former macrolide is not a CYP3A inhibitor or substrate.
Rifampin is the prototype of a strong enzyme inducer and is often difficult to combine with CYP substrates such as telaprevir and boceprevir. The AUC of telaprevir in combination with rifampin was reduced by 92% when compared to telaprevir alone, and this combination is contraindicated [15]. Boceprevir has not been tested with rifampin, but a contraindication also applies.
Methadone/buprenorphine
Because (former or current) intravenous drug use is a major transmission route for HCV, a considerable number of patients who are receiving opiate substitution therapy and/or actively using illicit drugs will be considered for therapy with DAAs. Hence there is a risk for a drug–drug interaction. Methadone is commonly used in opiate substitution programs and has been extensively studied. Telaprevir reduced methadone levels on average by 29%, but this effect is most probably attributed to displacement of methadone from plasma protein-binding sites [17]. Free, active concentrations of methadone remained largely unchanged. A somewhat smaller decrease in methadone levels was seen with boceprevir: AUC and Cmax were reduced by 22% and 15%, respectively; free methadone levels were not reported [18]. Surprisingly, the use of peg-interferon alfa appeared to cause a small increase in methadone levels of about 15%, which is unlikely to be associated with the need for a dose reduction to prevent methadone toxicity. Taking these apparently opposite effects of telaprevir/boceprevir and peg-interferon alfa together, close monitoring might be prudent in patients on methadone, when HCV combination therapy is initiated. Importantly, there should be a low threshold for methadone dose adjustment based on patient responses. In some centers, patients and their friends who are being considered for antiviral therapy are provided with opiate antagonists (naloxone), along with instructions for their use and this may be a prudent precaution in individuals with erratic consumption of illicit opiates.
Buprenorphine is an alternative to methadone for patients with opiate addiction. It has multiple metabolic pathways, including CYP3A, so an increase in plasma concentrations was possible when combined with CYP3A inhibitors such as telaprevir or boceprevir. However, buprenorphine levels were not increased when this was combined with telaprevir and also no signs of toxicity were observed [19]. Boceprevir caused a minor increase in buprenorphine AUC (+19%) which was associated with a 45% decrease in the AUC of norbuprenorphine, demonstrating an effect of boceprevir on this CYP3A pathway [18]. These changes, however, are not considered clinically relevant.
Buprenorphine is also available in a fixed-dose combination with naloxone. Systemic bioavailability of oral naloxone is very low (<3%) due to extensive first-pass metabolism (mainly UDP-glucuronosyltransferase (UGT) and partly CYP3A). Boceprevir increased naloxone AUC by 33%, suggesting that bioavailability of naloxone is somewhat improved when these agents are co-administered [18].
Antidepressants
It is generally accepted that the use of peg-interferon alfa can lead to psychiatric disorders including depression. Concomitant use of antidepressants with HCV treatment will thus not be a rarity and this poses the risk for a drug–drug interaction with DAAs, as both groups are CYP substrates. Escitalopram has been studied for the prevention of peg-interferon-induced depression and was, therefore, a logical candidate to be tested for a drug interaction with HCV protease inhibitors. With telaprevir, no change occurred in telaprevir levels, but escitalopram levels were decreased by an average of 35% [20]. When initiating escitalopram in a patient on telaprevir, one should dose titrate high enough before concluding that the antidepressant is not effective. The effect of boceprevir on escitalopram had the same direction as with telaprevir, although the magnitude of the decrease in AUC was smaller (−17%) [21].
It is unlikely that all patients can be effectively treated with escitalopram, and clinicians may have preferences for other antidepressants based on personal experience. Some of these agents (e.g., sertraline and mirtazepine) are CYP3A substrates and increased plasma concentrations of the antidepressant may occur when combined with telaprevir or boceprevir. Other antidepressants are more selectively metabolised by CYP2D6 (e.g., paroxetine, duloxetine and fluoxetine) and their pharmacokinetics are expected not to be influenced by telaprevir and boceprevir as the latter agents do not possess CYP2D6 inhibitory activity. More research is needed in this area.
Sedatives
A number of benzodiazepines are heavily dependent on CYP3A for their metabolism and interactions with boceprevir and telaprevir can be expected. Midazolam is a prototype CYP3A substrate, but is also relevant here as it is being used as premedication before endoscopy or gastroscopy. The AUC of oral midazolam was increased 9-fold with telaprevir [22] and 5.3-fold with boceprevir [2] and, therefore, oral midazolam is contraindicated with both DAAs. The magnitude of an interaction with parenteral midazolam is less than that observed with oral midazolam, as the inhibition of presystemic CYP3A metabolism is no longer relevant. Indeed, midazolam AUC increased only 3.4-fold when i.v. midazolam was added to telaprevir (vs. 9-fold with oral midazolam, see above) and there was no change in Cmax of midazolam [22]. Administration of 50% of the normal parenteral dose in patients on boceprevir or telaprevir is probably safe.
Other oral benzodiazepines such as triazolam and alprazolam [23] are contraindicated. Zolpidem levels were reduced by approximately 50% with steady-state telaprevir, so possibly a higher dose of zolpidem is needed [23]. Ketamine is extensively metabolised in the liver by various CYP enzymes and consequently, if CYP3A is involved, there are potentially multiple escape pathways. Propofol is mainly eliminated renally and, therefore, no interaction with DAAs is expected.
Statins
Most statins are also CYP3A substrates and, not surprisingly, CYP3A inhibitors such as telaprevir and boceprevir are expected to increase statin levels and the associated risk of severe toxicity such as rhabdomyolysis. Indeed, atorvastatin levels were elevated almost eight times with telaprevir [24]. This combination is a contra-indication, as is simvastatin, which has not been tested. The effect of boceprevir on atorvastatin was less strong: statin levels increased 2.3 times and this interaction appears to be manageable by starting with a low dose of atorvastatin (10mg) [25]. An alternative option might be pravastatin as this statin is not a CYP substrate. Pravastatin levels were marginally increased when combined with boceprevir (1.5-fold), probably caused by inhibition of the organic anion-transporting polypeptide (OATP) 1B1 [25], [26]. There are no data on rosuvastatin and HCV protease inhibitors.
Some clinicians have the opinion that, given the relatively short treatment duration with DAAs, at least with telaprevir (12weeks), one can also temporarily stop the statin to avoid toxicity associated with a potential drug–drug interaction.
Cardiovascular agents (other than statins)
Calcium entry blockers are known CYP3A (and partly also P-gp) substrates and thus increased exposure can be expected with CYP3A inhibitors such as telaprevir and boceprevir. This was also observed: amlodipine levels increased 1.8-fold when combined with telaprevir [24]. It is advised to start with a low dose of amlodipine (5
Some of the calcium entry blockers have very low systemic bioavailability (4–8%: barnidipine, lacidipine, lercanidipine) due to extensive first-pass metabolism. However, when combined with CYP3A inhibitors, such as telaprevir or boceprevir, systemic exposure may easily increase several-fold; therefore, these agents should not be used as a first choice.
Diuretics, angiotensin converting enzyme inhibitors (ACE) and angiotensin II receptor antagonists (AT1) are all classes of agents without extensive CYP metabolism, and hence combination with telaprevir and boceprevir is not expected to be problematic. β-receptor blocking agents are also not expected to cause problems as they are mainly eliminated renally (e.g., atenolol and sotalol) or metabolised through CYP2D6 (e.g., metoprolol and carvedilol). Anti-arrhythmics have a narrow therapeutic window and some are CYP3A substrates (e.g., amiodarone and bepridil). These are contraindicated with the strong CYP3A inhibitor telaprevir and caution is warranted with the moderate CYP3A inhibitor boceprevir.
Digoxin has been tested with telaprevir [22] and boceprevir [27] as a prototype P-gp substrate: digoxin levels were increased by 85% with telaprevir so this DAA can be defined as a moderate P-gp inhibitor and one should start with a low-dose digoxin in a patient on telaprevir. With boceprevir, the impact on digoxin levels was less than with telaprevir: AUC and Cmax of digoxin were increased by 19% and 18%, respectively. This suggests that boceprevir is a very mild P-gp inhibitor.
Antidiabetics
Use of antidiabetics should be monitored carefully in patients with hepatic impairment to avoid the occurrence of severe hypoglycaemia. Repaglinide is one of the few oral antidiabetics that is partially metabolised by CYP3A and theoretically could interact with the CYP3A inhibitors boceprevir and telaprevir. Repaglinide’s primary route of metabolism, however, is CYP2C8. This would be the escape pathway in the presence of a CYP3A inhibitor; therefore, no interaction with DAAs through this mechanism is expected. Repaglinide is also a substrate for OATP transporters and may consequently interact with DAAs in a non-CYP mediated mechanism. Some other oral antidiabetics are also metabolised by the liver, but not the CYP3A iso-enzyme. For instance, glimepiride is a CYP2C9 substrate, but this enzyme is not influenced by boceprevir [26] or telaprevir. Metformin is not expected to cause a problem when combined with DAAs.
Other agents
Finally, in this paragraph some agents are described that did not fall in one of the main therapeutic areas that are listed above. This includes either agents that have been tested or those with a contraindication based on theoretical considerations.
Plasma concentrations or the estrogen component of oral contraceptives are reduced by about 25–30% when combined with boceprevir [16] or telaprevir [28], and it is recommended to take additional (non-hormonal) precautions to prevent pregnancy. This is not only based on the observed drug interaction data, but also because HCV therapy includes ribavirin, which is teratogenic. Therefore, pregnancy should also be avoided from that important perspective.
The following agents are contraindicated with telaprevir and boceprevir because these agents are strongly dependent on CYP3A for metabolism and have a narrow therapeutic range: alfusozin, cisapride, ergotamin and derivates and pimozide.
Colchicine is another CYP3A substrate with a narrow therapeutic range; the drug labels contain a dosing algorithm for combined use of DAAs with colchicine, depending on its indication.
Besides rifampin, other strong enzyme inducers are carbamazepine, phenytoin, phenobarbital and St John’s wort; these inducers should not be combined with DAAs to avoid the occurrence of subtherapeutic levels of DAAs. Alternative anti-epileptic agents, such as valproic acid, levetiracetam and lamotrigine, are not enzyme inducers or CYP3A substrates. Therefore, they should be easier to combine with DAAs.
Phosphodiesterase type 5 inhibitor (PDE5) inhibitors such as sildenafil and tadalafil are CYP3A substrates and toxic levels can occur when combined with telaprevir or boceprevir. When these agents are applied at high doses for treatment of pulmonary hypertension, they are contraindicated with DAAs. However, for their use in erectile dysfunction, lower doses and/or less frequent dosing should be safe: sildenafil, 25mg per 48h; tadalafil, 10mg per 72h; vardenafil, 2.5mg per 24h (boceprevir) or 2.5mg per 72h (telaprevir). The proton pump inhibitor esomeprazole does not influence telaprevir exposure. Ibuprofen and diflunisal analgesic agents are interesting in this perspective as they are known to be AKR inhibitors, and AKR is responsible for part of boceprevir’s metabolism. A drug–drug interaction study, however, did not show an effect of diflunisal or ibuprofen on boceprevir pharmacokinetics [4].
An overview of the drug interactions with frequently used co-medications in HCV-infected patients is shown in Table 1.
Table 1. Overview of drug interactions with frequently used co-medications in HCV-infected patients. (See below-mentioned references for further information.)
CI, contraindicated; BOC, boceprevir; TVR, telaprevir; RBV, ribavirin; IFN, interferon; IV, intravenous; HCV PI, hepatitis C virus protease inhibitor; INR, international normalized ratio; Y, yes
Limitations of current drug interaction data
Many of the above-mentioned drug–drug interaction studies have been performed in healthy volunteers to avoid potential harm to patients who are at risk for toxicity or subtherapeutic effects when potentially interacting drugs are combined. This assumes that the effect of a certain drug–drug interaction is similar in healthy subjects as in an HCV-infected patient. This might not always be the case. For instance, HCV-infected patients with cirrhosis may also have impaired CYP450 capacity and have higher plasma concentrations of CYP450 substrates than healthy subjects. Theoretically, this would mean that they are at even more risk for drug toxicity when a drug–drug interaction occurs that is based on CYP450 inhibition, but at lower risk for subtherapeutic effects when a drug–drug interaction is based on enzyme induction, impaired absorption, etc. Nevertheless, extrapolation from healthy subjects to patients is still considered to be the norm, although in individual cases therapeutic drug monitoring, if available, might be helpful to assess the clinical relevance for that specific patient.
Conclusions
This overview illustrates that drug–drug interactions are an important and potentially frequent problem when using DAAs in clinical practice. It also shows, however, that many of the interactions are manageable by either dose adjustments or selecting a safe alternative, but only if one has sufficient knowledge and expertise to deal with these pharmacokinetic issues. The aim of this review was to provide this insight, as well as to raise awareness that drug–drug interactions in modern HCV treatment may have unwanted effects, such as increased toxicity or lack of therapeutic effect. This is of course most likely to have an impact on patients on multiple medications and/or treated by multiple physicians. Whenever one doubts about the safety of a certain combination, one should consult a pharmacist or clinical pharmacologist.
Financial support
We thank Gardiner-Caldwell Communications for general styling and co-ordination support, which was funded by Janssen Pharmaceuticals.
Conflict of interest
DBu has received research grants, honoraria for advisory boards and speakers fees from Merck and Tibotec/Janssen.
DBa has received research grants, honoraria for advisory boards and speakers fees from Merck, Janssen and Vertex.
PB has received speakers fees from Merck, Janssen, Bristol-Myers Squibb and Roche.
MB has been an investigator in clinical trials and advisor from Janssen and Merck.
HK has received research grants from Abbott, Boehringer, Bristol-Myers Squibb, Gilead, Janssen, MSD, Novartis, Roche, honoraria and speakers fees from Abbott, Boehringer, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Novartis, Roche and ViiV.
SP has received consulting and lecturing fees from Bristol-Myers Squibb, Boehringer Ingelheim, Janssen, Gilead, Roche, Schering-Plough/Merck, Novartis, Abbott, Sanofi and GlaxoSmithKline, and grants from Bristol-Myers Squibb, Gilead, Roche and Merck/Schering Plough.
MP has received consulting and lecturing fees from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD, Roche; has been an investigator in clinical trials for MSD, Janssen, Roche, Boheringer Ingelheim, Bristol-Myers Squibb and has received a research grant from Gilead Sciences.
MRG has received research grants from Abbott and Roche; and consulting and lectures fees from Bristol-Myers Squibb, Ipsen Farma, Janssen, Gilead, Roche, Schering-Plough/Merck, Novartis, Abbott, Digna Biotech, Transgene and GlaxoSmithKline.
SZ has consulted for Abbott, Achillion, Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, Idenix, Janssen, Merck, Novartis, Presidio, Roche, Santaris, Vertex.
All other authors have not provided a conflict of interest.
No comments:
Post a Comment